A phase II trial of IV [intravenous] busulfan (Busulfex) and melphalan as a preparatory regimen prior to allogeneic bone marrow transplantation [BMT] for the treatment of advanced and high risk hematologic malignancies.

Trial Profile

A phase II trial of IV [intravenous] busulfan (Busulfex) and melphalan as a preparatory regimen prior to allogeneic bone marrow transplantation [BMT] for the treatment of advanced and high risk hematologic malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2013

At a glance

  • Drugs Busulfan (Primary) ; Melphalan (Primary) ; Methotrexate
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2009 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top